Entries by Linda


Genoptix’s Immuno-Oncology Testing Now Covers Additional Tumor Types

Tests Can Identify More Cancer Patients Eligible for Merck’s KEYTRUDA® Therapy CARLSBAD, Calif., July 6, 2017 — Genoptix, Inc., a leading oncology diagnostics laboratory and informatics company, today announced that it offers three diagnostic tests that support immunotherapy decisions for solid tumor cancers. The tests include a companion diagnostic test for PD-L1 22C3 pharmDx, plus […]

, ,

Ampersand Capital Partners and 1315 Capital Close Transaction to Acquire Genoptix

Experienced management team co-invests with leading private investors to acquire premier oncology diagnostics and informatics services company CARLSBAD, Calif., March 7, 2017 — An experienced management team, led by Joseph M. Limber, in partnership with Ampersand Capital Partners and 1315 Capital, has completed the acquisition of Genoptix, Inc. from Novartis. The financial terms of the transaction are not […]